Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in its Fourth Venture Fund

Catalio Capital Management 在其第四只风险基金中筹集了超过 4 亿美元，用于投资创新的医疗保健公司。

Continues Successful Strategy of Discovering and Investing in Breakthrough Biomedical Technologies Around the Globe

继续成功实施在全球范围内发现和投资突破性生物医学技术的战略

NEW YORK, July 1, 2025-- Catalio Capital Management, LP (“Catalio”), a leading innovative healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV (“Fund IV” or the “Fund”), with over $400M in commitments across the Fund and its related co-investment vehicles.

纽约，2025年7月1日——领先的投资医疗创新的公司Catalio资本管理公司（“Catalio”）今天宣布成功关闭其第四只风险基金，Catalio Nexus Fund IV（“Fund IV”或“该基金”），该基金及其相关共同投资工具共获得了超过4亿美元的承诺。

The Fund received significant backing from current Catalio investors as well as new, global institutional investors, RIAs, foundations and endowments..

该基金获得了现有 Catalio 投资者以及新的全球机构投资者、注册投资顾问（RIAs）、基金会和捐赠基金的大力支持。

The fundraise marks a significant milestone for Catalio, reinforcing investor confidence in its differentiated strategy of backing breakthrough biomedical technology companies founded by serial scientist-entrepreneurs. Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, the firm manages $2 billion in assets across its private equity, private credit, and public equities strategies..

这次融资标志着Catalio的一个重要里程碑，进一步巩固了投资者对其差异化战略的信心，该战略支持由连续创业的科学家创立的突破性生物医学技术公司。Catalio由联合创始人乔治·彼得罗希洛斯和雅各布·沃格尔斯坦博士于2020年创立，公司管理着横跨私募股权、私人信贷和公共股票策略的20亿美元资产。

“We are grateful for the continued confidence and strong support we received for Fund IV from both new and existing high caliber investors,” said Olga Maltseva, Partner & Head of Operations at Catalio, who oversees the firm’s marketing division. “These new funds will allow Catalio to continue taking advantage of opportunities in a historic buyer’s market in biotech, and to keep distinguishing ourselves as a leading innovative healthcare investor around the globe.”.

“我们非常感谢新老高素质投资者对第四基金持续的信任与大力支持，”Catalio的合伙人兼运营主管奥尔加·马尔采娃说道，她负责公司的营销部门。“这些新资金将使Catalio能够继续利用生物技术领域历史性的买方市场机遇，并在全球范围内巩固我们作为领先的创新医疗保健投资商的地位。”

Catalio’s core investment approach remains centered on identifying and supporting transformative healthcare companies spun out of leading academic institutions and led by repeat founders with deep scientific expertise. Its Nexus funds have backed more than 80 private companies since Catalio’s founding five years ago and have sold or taken public a number of businesses over the years, making distributions to their limited partners every year since the firm’s inception..

Catalio 的核心投资策略仍然集中在识别和支持由领先学术机构分拆出来的、由具有深厚科学专业知识的连续创业者领导的变革性医疗保健公司。自 Catalio 五年前成立以来，其 Nexus 基金已支持了 80 多家私营企业，并在多年间出售或上市了多家企业，自公司成立以来每年都向其有限合伙人进行分配。

To date, Fund IV has made 16 investments, continuing the firm’s track record of partnering with world-class teams and building category-defining life sciences businesses at all stages, from inception to IPO and beyond.

迄今为止，第四基金已进行了16项投资，延续了该公司与世界级团队合作的记录，并在从创立到首次公开募股及以后的所有阶段，建立定义类别的生命科学企业。

“We continue to see many compelling investment opportunities in this current market, including deals with prospects for near-term liquidity and deals with prospects for long-term growth,” said Dr. Diamantis Xylas, Partner & Head of Research at Catalio. “We are proud to invest in breakthrough biomedical technology companies developing drugs, devices, diagnostics, and tools that have potential for broad clinical impact and can enhance the lives of millions of patients around the world while delivering meaningful returns for our investors,” he said..

“我们在这个当前市场中继续看到许多引人注目的投资机会，包括具有短期流动性的交易和具有长期增长前景的交易，”Catalio的合伙人兼研究主管迪亚曼蒂斯·西拉斯博士表示。“我们很自豪能够投资于开发药物、设备、诊断工具和技术的突破性生物医学技术公司，这些公司具有广泛的临床影响潜力，可以改善全球数百万患者的生活，同时为我们的投资者带来可观的回报，”他说道。

Recent highlights in Fund IV include:

基金IV的近期亮点包括：

• Co-leading PinkDx’s $40 million Series A fundraise aimed at developing diagnostics for gynecological cancers, building on Catalio’s extensive track record of success in cancer diagnostics.

• 共同领导PinkDx的4000万美元A轮融资，致力于开发妇科癌症诊断技术，依托Catalio在癌症诊断领域的成功经验。

• Investing in the Series A financing of Superluminal Medicines, augmenting Catalio’s portfolio of AI-enabled drug discovery companies.

• 投资Superluminal Medicines的A轮融资，增强Catalio在人工智能驱动的药物发现公司领域的投资组合。

• Launching two new companies focused on immunology and inflammation: Rhapsogen, co-founded by Catalio Venture Partner Dr. Jeffrey Ravetch at Rockefeller University; and TBD Pharma, co-founded by Catalio Venture Partner Dr. Bert Vogelstein at Johns Hopkins University.

• 推出两家专注于免疫学和炎症的新公司：Rhapsogen，由Catalio风险合伙人Dr. Jeffrey Ravetch在洛克菲勒大学共同创立；以及TBD Pharma，由Catalio风险合伙人Dr. Bert Vogelstein在约翰霍普金斯大学共同创立。

• Taking advantage of attractive valuations in late-stage companies by participating in the $150M Series E financing for Imperative Care, a medical device company; a PIPE for Protara Therapeutics (NASDAQ:TARA), an oncology company; and the $180M Series D financing for Alentis Therapeutics, a company developing antibody drug conjugates (ADC) for oncology indications..

• 利用晚期公司的诱人估值，参与了医疗设备公司Imperative Care的1.5亿美元E轮融资、肿瘤学公司Protara Therapeutics（纳斯达克股票代码：TARA）的PIPE融资，以及开发用于肿瘤适应症的抗体药物偶联物（ADC）的Alentis Therapeutics公司的1.8亿美元D轮融资。

About Catalio Capital Management, LP:

关于Catalio资本管理，LP：

Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public and credit markets. Catalio has exclusive partnerships with world-renowned serial scientist-entrepreneurs from around the globe who each have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research.

Catalio Capital Management, LP是一家总部位于纽约的投资公司，专注于在私人、公开和信贷市场中进行创新医疗投资的全生命周期。Catalio与来自全球的世界知名连续创业科学家建立了独家合作伙伴关系，这些科学家均拥有广泛的学术和科学成就，并基于他们的研究创立了多家成熟的公司。

Catalio has offices in New York, London, and Washington, D.C. Learn more about Catalio Capital Management by visiting www.cataliocapital.com..

Catalio在纽约、伦敦和华盛顿特区设有办事处。请访问www.cataliocapital.com以了解更多关于Catalio资本管理的信息。

Contact:

联系人：

Charles V. Zehren

查尔斯·V·泽伦

631-681-7107

631-681-7107

czehren@rubenstein.com

czehren@rubenstein.com